Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials SAN FRANCISCO & NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE) ...

Researchers monitored participants for one year and found the device to be safe, with no serious adverse events that led to disability or death. Stentrode™ also stayed in place for all four patients ...

California Start-up Synchron recently published its study and findings in the success of the "Stentrode" Brain chips implanted in the blood vessels of paralyzed and disabled patients to help them ...

US-based Synchron has secured $200m in a Series D funding round to drive the commercial rollout of its Stentrode brain-computer interface (BCI) platform and aid in the creation of next-generation ...

Thanks to the success of an initial safety trial for an implantable device that can translate the brain’s electrical impulses into readable signals, we’re a step closer to being able to text—or ...

Patient Graham Felstead knew this was uncharted territory. “We were told in no uncertain terms, ‘He may not come out of this operation’,” says wife Nancy Felstead. But Graham was more than willing to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SAN FRANCISCO and NEW YORK CITY and MELBOURNE, Australia, Sept. 20 2019 /PRNewswire/ -- Synchron Inc. today announced the first successful clinical implantation of the Stentrode®, a minimally-invasive ...

Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials Synchron, a neurovascular bioelectronics medicine company, today ...

NEW YORK--(BUSINESS WIRE)--Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ ...

Neurovascular bioelectronics medicine company Synchron Inc. has received good news in the form of a breakthrough device designation for its Stentrode. The U.S. FDA granted the designation for the ...